CRB INNOVATION IS BASED ON A METABOLIC APPROACH AS THE ROOT CAUSE OF CANCER
Many theories have emerged to explain the root cause of cancer. The somatic mutation hypothesis depicts DNA mutations as the first and main cause of cancer initiation. The Warburg theory describes the mitochondrial metabolic pathways as the upstream mechanisms that lead to DNA mutations, which in turn leads to cancer. In other words, environmental factors affect other parts of the cell, such as mitochondria, before reaching the DNA.
If we can keep mitochondria in balance, we can protect DNA from developing irreversible mutations that lead to severe diseases, including cancer.
At CRB, we aim to treat cancer patients by restoring the metabolic functions of the cell. This will help to eradicate cancer cells, reduce the metastatic spreading of tumors, and avoid cancer recurrence.
OUR FIRST DRUG IS FOR METASTATIC MELANOMA
Metastatic Melanoma is an aggressive and highly metastatic disease, efficient in evading immune response. After reaching metastatic stage, survival is only around 20%.
Current treatment challenges are due to tumor heterogeneity, acquired resistance to treatment, immune evasion and toxicity. There is a need for novel options and combinatorial choices for successful and well tolerated treatments.
PRE-CLINICAL TRIALS
CRB091 IN METASTATIC MELANOMA:
PRE-CLINICAL TRIALS
CRB’s first oncology drug, CRB091, targets metastatic melanoma tumors by selectively eradicating cancer cells, without inducing toxicity in healthy organs. The pre-clinical research of CRB091 showed significant results on human cancer cell lines in both efficacy and safety.
CRB has drawn a clear path to first in-human, and will soon launch clinical trials Phase 1.
